Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market trading after the company announced it will engage in strategic restructuring and cost savings.

Benzinga

Johnson & Johnson Credits Tariff Delays For Strong Earnings, While Jim Cramer Pegs It On 'Lower Than Thought' Levies

Johnson Johnson (NYSE:JNJ) delivered better-than-expected second quarter results, with the management hinting at leveraging tariff delays to maintain its outlook; however, CNBC’s Jim Cramer credited the performance to lower tariffs.

Benzinga

How 340B Drug Discounts Are Driving Up Medicaid Costs By Billions

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it’s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:NVO).

Benzinga

Why Is Kairos Pharma Stock Surging On Tuesday?

Kairos Pharma, Ltd. (NYSE:KAPA) stock is trading higher on Tuesday, with a strong session volume of 221 million compared to the average volume of 874.3K as per data from Benzinga Pro.

Benzinga

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday posted a fourth-quarter 2025 adjusted loss of 3 cents per share, compared to the consensus for a per-share loss of 12 cents.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

Bristol-Myers Squibb Co. (NYSE:BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from Benzinga Pro.

Benzinga

Becton's Biosciences And Diagnostics Arm Slated To Join Waters In $17.5 Billion Merger

Becton, Dickinson and Company (NYSE:BDX) has agreed to combine its Biosciences Diagnostic Solutions business with Waters Corporation (NYSE:WAT).

Benzinga

Top 3 Health Care Stocks That Could Blast Off In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga

Medtronic Stock Is Climbing Friday: What's Going On?

On Wednesday, the Centers for Medicare Medicaid Services (CMS) proposed a significant step toward broader adoption of renal denervation (RDN) by offering coverage for both radiofrequency (rfRDN) and ultrasound (uRDN) technologies for uncontrolled hypertension. This coverage would be granted under a Coverage with Evidence Development (CED) framework, requiring treatment within…

Benzinga

Why Is Milestone Pharmaceuticals Stock Plunging On Friday?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) moved closer to potential FDA approval for its Cardamyst (etripamil) nasal spray, an investigational therapy for paroxysmal supraventricular tachycardia (PSVT), as the U.S. Food and Drug Administration (FDA) accepted the company’s response to prior issues.

Benzinga

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday.

Benzinga

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging that Zantac, or its generic ranitidine, can cause cancer.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to “benefit” from the levies.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie Inc. (NYSE:ABBV), on Thursday, announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT protein platform, for oncology and autoimmune diseases.

Benzinga

Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Shares of The AES Corporation (NYSE:AES) rose sharply in pre-market trading following reports the company has received takeover interest.

Evening Standard

Government suing PPE Medpro because of ‘buyer’s remorse’, court told

The Department of Health and Social Care wants PPE Medpro to repay more than £120 million over an alleged breach of contract.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket

Shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) rose sharply in pre-market trading after the company announced it will be granted a US patent titled “Radio Frequency Applicator”.

Benzinga

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:LLY) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its…

Benzinga

What's Going On With AMD Stock?

Advanced Micro Devices Inc. (NASDAQ:AMD) shares are down more than 2% Monday, pulling back after climbing more than 16% over the past month. Here’s a look at what could be fueling the recent run.

AAP

At-home drug test offers workers more autonomy

Simple at-home drug testing kits are helping employees "do the right thing before it becomes a problem", their creators say.

Benzinga

MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares soared to $1.87, an approximate 50.8% jump, during after-hours trading on Wednesday.

The Guardian - UK

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Independent UK

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.